(#33) Earlier Use of Long-Acting Injectable Paliperidone Palmitate versus Oral Antipsychotics in Patients With Schizophrenia: A Post-hoc Analysis From PROSIPAL

Abstract: Objective: The analysis evaluated outcomes following initiation of paliperidone palmitate 1-month (PP1M) vs oral antipsychotics (OAPs) within ?3-years and >3-5-years of a schizophrenia diagnosis. Methods: The PROSIPAL (Prevention of Relapse with Oral Antipsychotics versus Injectable Paliperidone Palmitate) study, which enrolled patients with a recent diagnosis of schizophrenia, was utilized for this analysis to assess risk of relapse and outcomes related to symptoms, functionality, & satisfaction. Results: The risk of relapse was reduced by 31% for PP1M versus OAP in ?3-years group (HR 0.69; 95% CI 0.44-1.07) and by 40% with PP1M vs OAP in >3-5 years group (HR 0.60; 95% CI 0.33-1.08). For the ?3-years group, improvements were observed with PP1M versus OAP at the endpoint in PANSS total score (mean change -16.8 vs -13.2, p=0.044), PSP total score (mean change 10.5 vs 7.7, p=0.031), TSQM-convenience subscale (5.8 vs 0.7, p=0.025), Physician Treatment Satisfaction-mode of administration subscale (mean change -0.5 vs 0.1, p < 0.001), and overall satisfaction (mean change -0.2 vs 0.1, p=0.014). For the >3-5-group, improvements were observed with PP1M versus OAP at the endpoint in TSQM-convenience (mean change 10.3 vs -0.5, p < 0.001) and Physician Treatment Satisfaction-mode of administration (mean change -0.6 vs -0.2, p=0.004). Treatment-emergent adverse events rates were similar between treatment groups regardless of duration of illness. Conclusion: PP1M reduced the risk of relapse and greater improvements in certain symptoms, functionality, & satisfaction outcomes regardless of duration of treatment compared to OAPs, reinforcing the importance of early adoption and implementation of PP1M post-schizophrenia diagnosis.Short Description: This post-hoc analysis from PROSIPAL examined the risk of relapse, symptom severity (PANSS and CGI-S), functional outcomes (PSP), and treatment satisfaction (TSQM and Physician Treatment Satisfaction) following initiation of PP1M versus OAP within ?3-years and >3-5-years of a schizophrenia diagnosis. PP1M reduced the risk of relapse and showed greater improvements in select symptomatology, functional capacity, and satisfaction measures compared with OAPs in both treatment groups.Name of Sponsoring Organization(s): Janssen Scientific Affairs, LLC, a Johnson & Johnson company